GHRH receptor agonist
Tesamorelin
TH9507 — trans-3-hexenoyl-GHRH(1-44) amide (GHRH analogue)
Overview
Tesamorelin (TH9507) is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH) with a stabilising trans-3-hexenoyl modification at the N-terminus. It binds the GHRH receptor on pituitary somatotrophs and stimulates the body's own pulsatile release of growth hormone (GH), which in turn raises hepatic IGF-1.
Research contexts include visceral (deep-belly) fat reduction, body composition and lean-mass preservation, and improvements in triglycerides and non-HDL cholesterol. Because the pituitary is signalled to release its own GH rather than replacing it directly, negative-feedback loops through IGF-1 and somatostatin remain intact — the tolerability profile in research contexts is generally milder than high-dose exogenous rhGH.
The compound is a research-use lyophilized peptide reconstituted with bacteriostatic water for repeated-access subcutaneous use, per the standard Healthy Mango preparation convention.
Quick Facts & Evidence
- Category
- GHRH receptor agonist
- Research area
- GHRH analogue
- Most studied for
- Visceral (deep-belly) fat reduction
- Body-composition research (lean mass preservation)
- Hepatic fat and lipid profile
- Preservation of pulsatile GH release as an alternative to exogenous rhGH
- Clinical status
- Investigational
- Human evidence
- Moderate Human Evidence
- Regulatory status
- Not approved by FDA, EMA or MHRA
Moderate Human Evidence
Supported by human trials, but of limited size, duration, or replication. May be approved for related but not identical indications.
Research Protocols
Research Protocol Snapshot
Preparation covered on this page
Freeze-dried injectable research format
This page covers the RUO lyophilized tesamorelin vial reconstituted with bacteriostatic water for repeated-access subcutaneous research use, following the standard Healthy Mango preparation convention.
Tesamorelin research values at a glance.
| Item | Example value |
|---|---|
| Vial size | 10 mg |
| Liquid used to mix | Bacteriostatic water |
| Amount of liquid added | 2.0 mL |
| Final concentration | 5 mg/mL |
| How it's given | Subcutaneous injection |
| Research dose | 2 mg |
| Frequency | Once daily |
| After mixing | Refrigerate; use within 7–10 days |
Reported Dosing
One research protocol is documented for this format. It is educational reference, not a recommendation.
The Reported Protocol
| Dose | Frequency | Duration | Notes |
|---|---|---|---|
| 2 mg | Once daily, subcutaneous | Continuous (no established cycling protocol) | 0.4 mL at 5 mg/mL |
Why protocols vary
A single research-context protocol is documented for this format: 2 mg once daily, subcutaneous. Cycling is not established — the dosing is described as continuous.
At the standard 5 mg/mL reconstitution, the 2 mg amount corresponds to 0.4 mL, which is why the 10 mg + 2.0 mL preparation is the convention across the peptide-therapy space.
Preparing the Solution
Turning the freeze-dried powder into a measurable liquid.
Documented preparation
The documented research protocol is based on this preparation concentration.
Freeze-dried powder: 10 mg vial
Diluent: 2.0 mL bacteriostatic water
Final concentration: 5 mg/mL
Vial and volume from the practitioner reference; concentration calculated · Research-practitioner guide
Your vial
Matching preparation
Bacteriostatic water
2mL
Resulting concentration
5 mg/mL
Equivalent volume
The reported research amount of 2 mg is contained within
0.4mL
of the prepared solution now in your vial.
Show calculation
- Documented concentration
- 10 mg ÷ 2 mL = 5 mg/mL
- Bacteriostatic water to match the documented concentration
- 10 mg ÷ 5 mg/mL = 2 mL
- Equivalent volume at this concentration
- 2 mg ÷ 5 mg/mL = 0.4 mL
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.
This tool performs arithmetic conversions using the preparation example and reported research amount shown on this page. It does not recommend an amount, route, preparation method, or use.Sources for these values
- Documented in the practitioner referenceResearch-practitioner guide
This example explains how concentration and volume are calculated for the standard RUO preparation. It is not a preparation guide.
How It's Given
Method used for this format
Subcutaneous injection, once daily
Documented in the practitioner reference · Research-practitioner guide
Why this method
Tesamorelin is a peptide; the subcutaneous route delivers it into circulation without the gastrointestinal degradation that would break the molecule down.
Once-daily subcutaneous dosing matches the pulsatile GHRH signalling the compound is designed to mimic.
Injection sites reported
- Abdomen (rotate sites)
- Avoid scarred, bruised, inflamed, or infected skin
Storage
Before mixing
- Refrigerate 2–8 °C
- Protect from light
- Do not freeze
Documented in the practitioner reference; general RUO practice · Research-practitioner guide
After mixing
- Refrigerate 2–8 °C
- Use within 7–10 days
- Do not freeze
- Discard if cloudy or discoloured
Documented in the practitioner reference · Research-practitioner guide
Handling
- Direct diluent slowly down the vial wall
- Gently swirl until dissolved — do not shake
- New sterile needle each draw
- Do not share vials
General RUO practice · Research-practitioner guide
Storage guidance summarises documented practitioner practice and standard RUO peptide handling. Verify the specific vial's supplied instructions before use.
Common Cycle
Tesamorelin dosing is described as continuous daily use — not cycled.
- Cycle Length
- Continuous daily use
- Break Before the Next Cycle
- Not applicable — no established cycling protocol
- What the Research Shows
- Not defined
Documented in the practitioner reference · Research-practitioner guide
Effects are reported to be maintained with ongoing daily use; intermittent-dosing schedules discussed in body-recomposition contexts are not part of the documented protocol.
Compound Overview
Current areas of research
The following are the research contexts described for tesamorelin.
- Reduction of visceral (deep-belly) adipose tissue
- Improvement of triglycerides and non-HDL cholesterol
- Support of lean muscle mass in body-composition research
- Preservation of the body's own pulsatile GH release (contrast with exogenous rhGH replacement)
Mechanism of action
Tesamorelin (TH9507) is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone (GHRH) with a stabilising trans-3-hexenoyl modification at the N-terminus. It binds the GHRH receptor on pituitary somatotrophs and stimulates the body's own pulsatile release of growth hormone (GH), which in turn raises hepatic IGF-1.
Research contexts include visceral (deep-belly) fat reduction, body composition and lean-mass preservation, and improvements in triglycerides and non-HDL cholesterol. Because the pituitary is signalled to release its own GH rather than replacing it directly, negative-feedback loops through IGF-1 and somatostatin remain intact — the tolerability profile in research contexts is generally milder than high-dose exogenous rhGH.
The compound is a research-use lyophilized peptide reconstituted with bacteriostatic water for repeated-access subcutaneous use, per the standard Healthy Mango preparation convention.
- A full-length GHRH(1-44) analogue with a stabilising N-terminal modification
- Preserves the physiologic pulsatile GH pattern (vs direct rhGH replacement)
- Standard RUO preparation: 10 mg vial + 2.0 mL bacteriostatic water → 5 mg/mL
- Documented research dose: 2 mg once daily, subcutaneous
Human research
Tesamorelin's research context is anchored in its GHRH-analogue mechanism: pituitary GHRH-receptor activation drives the body's own pulsatile GH release, which in turn elevates hepatic IGF-1 and mediates the compound's characteristic effects on visceral fat, lipid profile, and lean mass.
Evidence level is Level B (moderate) — supported by a well-characterised mechanism and reproducible research-context effects in the GHRH-analogue peer-reviewed literature, without a formal RUO regulatory framework.
Tesamorelin is a research-use GHRH-analogue peptide, prepared as a lyophilized vial reconstituted with bacteriostatic water for subcutaneous research use.
Access is via research-supply or compounding-pharmacy channels; parameters (identity, mass, diluent, sterility, beyond-use date) should be verified from the dispensing source before use.
The mechanism (pituitary GHRH-receptor agonism → pulsatile GH → IGF-1 elevation) is well characterised. Research-context effects on visceral fat, body composition, and lipid profile are reproducible across the peer-reviewed GHRH-analogue literature.
Safety considerations
The following are commonly reported for GHRH-analogue compounds in the research literature.
- Injection-site reactions — Erythema, pruritus, pain, bruising — most common
- Arthralgia
- Myalgia
- Peripheral oedema
- Carpal tunnel-like symptoms — Paresthesia in hands or feet
- Fluid retention
- Hyperglycaemia / impaired glucose tolerance — Attributable to IGF-1 elevation; relevant to research participants with diabetes or prediabetes
- Rash
- Rare: severe hypersensitivity — Discontinue and seek medical care immediately
The contraindications below are drawn from the general safety profile for GHRH-analogue compounds. The dominant safety signals reported in the research literature are injection-site reactions and the metabolic effects of IGF-1 elevation.
- Disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumour or surgery, head irradiation, head trauma)
- Active malignancy — theoretical risk from IGF-1 elevation
- Pregnancy
- Known hypersensitivity to tesamorelin
Monitoring
- Baseline and periodic IGF-1 measurements
- Fasting glucose and HbA1c in research participants with diabetes or prediabetes
- Signs of fluid retention or new-onset carpal tunnel-like symptoms
- Injection-site reactions across rotation sites
Frequently asked questions
How is tesamorelin different from rhGH (recombinant human growth hormone)?
Recombinant human GH (rhGH) replaces GH directly, bypassing the pituitary. Tesamorelin acts one step upstream: it stimulates the pituitary to release its own GH in physiologic pulses. Because the negative-feedback loops through IGF-1 and somatostatin remain intact, tesamorelin generally shows a milder side-effect profile than high-dose rhGH — though it is still associated with IGF-1 elevation, fluid retention, and glucose changes.
What is the standard research preparation?
The documented preparation reconstitutes a 10 mg vial with 2.0 mL of bacteriostatic water, giving a 5 mg/mL solution. The documented research amount is 2 mg once daily by subcutaneous injection — 0.4 mL at that concentration.
How long does a reconstituted vial last?
The reconstituted vial is usable for approximately 7–10 days refrigerated. Only mix one vial at a time — do not reconstitute a full month's supply at once. Discard if the solution ever becomes cloudy or discoloured.
What happens to IGF-1 during tesamorelin research?
IGF-1 rises during administration; this is the expected pharmacology of a GHRH-analogue signal driving pituitary GH release. Research contexts commonly monitor IGF-1 periodically to keep it within an age-appropriate reference range.
How does tesamorelin compare to sermorelin?
Sermorelin is a shorter GHRH(1-29) analogue with a very short half-life (~10–20 minutes). Tesamorelin is a full-length GHRH(1-44) analogue with a stabilising trans-3-hexenoyl modification and a somewhat longer half-life (~26–38 minutes). See the Tesamorelin vs Sermorelin comparison for a structured side-by-side.
References
- [1]
Peptides & Compounds — The No-Jargon Guide (v5) — Healthy Mango Editorial, Healthy Mango practitioner reference (2026)
Laboratory Reference Notice
This section summarizes procedures and study parameters reported in published scientific literature and laboratory protocols. It is provided for educational and research reference only and must not be interpreted as medical advice, clinical guidance, or instructions for personal use.
Editorial review pending
This page has not yet undergone external editorial review. Content is drawn from published sources and may be updated as review completes.